RIGL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RIGL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Rigel Pharmaceuticals's purchase of property, plant, equipment for the three months ended in Sep. 2024 was $0.0 Mil. It means Rigel Pharmaceuticals spent $0.0 Mil on purchasing property, plant, equipment. Rigel Pharmaceuticals's purchase of property, plant, equipment for the trailing twelve months (TTM) ended in Sep. 2024 was $0.0Mil.
Compared with last quarter ($0.0 Mil in Jun. 2024 ), Rigel Pharmaceuticals spent the same money on purchasing property, plant, equipment in Sep. 2024 ($0.0 Mil).
The historical data trend for Rigel Pharmaceuticals's Purchase Of Property, Plant, Equipment can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rigel Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Purchase Of Property, Plant, Equipment | Get a 7-Day Free Trial | -1.46 | -1.26 | -0.63 | -0.45 | - |
Rigel Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Purchase Of Property, Plant, Equipment | Get a 7-Day Free Trial | - | - | - | - | - |
The amount used to purchase PPE.
Purchase Of Property, Plant, Equipment for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Rigel Pharmaceuticals's Purchase Of Property, Plant, Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.
David A Santos | officer: EVP, Chief Commercial Officer | RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080 |
Dean L Schorno | officer: EVP & Chief Financial Officer | 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063 |
Raul R Rodriguez | officer: Sr VP of Bus Dev and Com Ops | 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Wolfgang Dummer | officer: EVP & CMO | 5491 OPTICAL CT., SAN JOSE CA 95138 |
Raymond J. Furey | officer: EVP, GC & Corp Sec | 1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92807 |
Alison L. Hannah | director | 12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913 |
Gary A Lyons | director | 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130 |
Anthony Gregg Lapointe | director | PO BOX 83216, GAITHERSBURG MD 20883-3216 |
Brian L. Kotzin | director | RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA 94060 |
Kamil Ali-jackson | director | C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355 |
Jane Wasman | director | C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
Nelson Cabatuan | officer: Principal Accounting Officer | RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080 |
Anne-marie Duliege | officer: Chief Medical Officer | 4001 MIRANDA AVENUE, PALO ALTO CA 94304 |
Mayer Eldon C. Iii | officer: EVP & Chief Commercial Officer | RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080 |
Stacy Markel | officer: EVP Human Resources | RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080 |
From GuruFocus
By PRNewswire • 09-03-2024
By PRNewswire • 06-24-2024
By PRNewswire • 11-12-2024
By GuruFocus Research • 08-07-2024
By PRNewswire • 08-29-2024
By PRNewswire • 07-12-2024
By PRNewswire • 08-06-2024
By Marketwired • 10-16-2024
By GuruFocus News • 11-06-2024
By GuruFocus News • 11-07-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.